Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. Cell Immunol 2003 Mar;222(1):15-26
Date
06/12/2003Pubmed ID
12798304DOI
10.1016/s0008-8749(03)00079-0Scopus ID
2-s2.0-0038207050 (requires institutional sign-in at Scopus site) 29 CitationsAbstract
A murine model for neuroblastoma, Neuro-2a (N2a), was used to establish a model tumor vaccine. An aggressive subclone of N2a and the less aggressive parental line were transfected with CD80, CD86, or both molecules and stable lines were established. The less aggressive N2a expressing either CD80 or CD86 induced anti-tumor immunity. In contrast, dual expression of CD80 and CD86 was required to initiate a protective anti-tumor immune response against the aggressive subclone. Control of tumor growth was dependent on CD8+ lymphocytes that infiltrated dual-expressing (CD80 and CD86) lesions. These tumor-infiltrating lymphocytes (TIL) exhibited a non-classical mechanism of tumor cell lysis that may require both the up-regulation of cell surface molecules on the tumor and the subsequent lytic activity normally associated with CD8+ TIL. Although Fas was up-regulated by the tumor in the presence of IFN-gamma, N2a and transfected N2a cell lines were not sensitive to Fas-mediated lysis.
Author List
Johnson BD, Yan X, Schauer DW, Orentas RJAuthor
Bryon D. Johnson PhD Adjunct Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsAntigens, CD
B7-1 Antigen
B7-2 Antigen
Cancer Vaccines
Interferon-gamma
Lethal Dose 50
Lymphocytes, Tumor-Infiltrating
Membrane Glycoproteins
Mice
Neuroblastoma
Transfection
Tumor Cells, Cultured
Tumor Necrosis Factor-alpha
